The safety and efficacy of tolvaptan in children/adolescents with ADPKD has also been investigated in randomized controlled trial, which support the activity of tolvaptan at the vasopressin V2 receptor in children and adolescents with ADPKD [11]. This evidence concerns the gene AVPR2 and autosomal dominant polycystic kidney disease.